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Role for macrophage 
metalloelastase in Alport 
syndrome 
Alport syndrome is a genetic disorder aff ecting the glomerular 
basement membrane (GBM). X-linked Alport syndrome is 
caused by mutations in the COL4A5 gene, and the autosomal 
form, which displays the same range of phenotypes as the 
X-linked form, is due to mutations in either of the basement 
membrane collagen genes COL4A3 and COL4A4. Alport 
syndrome is characterized by a juvenile onset of proteinuria 
followed by changes in glomerular cell types, including 
eff aced podocyte foot processes and expansion of the 
mesangium. Th ese changes culminate in accumulation 
of extracellular matrix and fi brotic glomeruli. A hallmark 
of glomerular changes in Alport syndrome is an irregular 
thickening, thinning, and splitting of the GBM. Homeostatic 
extracellular matrix turnover is a delicately balanced system 
of coupled biosynthetic and degradative processes in which 
matrix metalloproteinases (MMPs) play an important role. 
Preliminary work had suggested a role for MMPs in renal 
pathogenesis of Alport syndrome.
MMP-12 (metalloelastase) is a potent protease with broad 
matrix substrate specifi city that has long been associated with 
macrophages and lung disease. In a recent article, Rao et al. 
show that MMP-12 is markedly induced in the glomeruli of 
Alport mice (see Figure), and that the degree of induction 
correlates well with the progression of glomerular disease. 
Treatment of Alport mice with a broad-spectrum MMP 
inhibitor that blocks MMP-12 activity largely restored 
GBM ultrastructure and function, whereas treatment with a 
broad-spectrum MMP inhibitor that does not inhibit MMP-12 
had no eff ect. Th ese results suggest that the cellular mechanism 
of MMP-12 induction might be linked to monocyte 
chemoattractant protein-1 (MCP-1)-mediated activation of the 
CCR2 receptor on glomerular podocytes; the CCR2 receptor 
antagonist propagermanium attenuates GBM thickening and 
preserves the integrity of the glomerular fi lter. Th e data suggest 
that irregular thickening of the GBM in Alport syndrome may 
be caused in part by proteolytic degradation of the GBM due to 
elevated expression of MMP-12 in glomerular podocytes. Th e 
cellular mechanism of MMP-12 induction (MCP-1 activation 
of CCR2 on glomerular podocytes) is quite unexpected and 
has been previously described only in macrophages. (Am J 
Pathol 2006; 169: 32–46)
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A gene required for development 
of metanephric mesenchyme
Vertebrate kidney derives from the intermediate mesoderm 
(IM), which gives rise to three types of kidney tissue, called 
(from anterior to posterior) the pronephros (a transient 
embryonic structure), the mesonephros (the functional 
embryonic kidney), and the metanephros (the defi nitive 
adult kidney). Kidney formation consists of two stages: 
establishment of nephrogenic mesenchyme within the IM and 
diff erentiation of that mesenchyme into functional nephrons. 
In the mouse metanephros, which is the best-studied example, 
diff erentiation of the mesenchyme occurs as the result of 
interaction between the metanephric mesenchyme, which 
is derived from the most posterior region of the IM, and the 
ureteric duct, another IM derivative that migrates into the 
metanephric zone from a more anterior region of the embryo. 
MMP-12 is upregulated in glomerular podocytes. Reprinted from Am. J. 
Pathol. 2006 169:32–46 with permission from the American Society for 
Investigative Pathology.
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Reciprocal signaling between the metanephric mesenchyme 
and the ureteric bud results in development of the kidney. 
Th e mechanisms that regulate the earlier phase of kidney 
development — formation of nephrogenic mesenchyme — are 
less understood. Multiple genes have been identifi ed that are 
expressed specifi cally in the undiff erentiated metanephric 
mesenchyme; many of these are required for proper 
diff erentiation of the metanephric kidney, including Pax2, 
Wt1, Eya1, Six1, the Hox11 paralogous group, and N-myc. 
However, with the exception of Eya1, all of the above genes 
are dispensable for the initial formation of the metanephric 
mesenchyme and are instead required for its subsequent 
diff erentiation and/or survival. 
In a new study, James et al. characterized the role 
during kidney formation of odd-skipped related 1 (Odd1), 
a zinc fi nger-containing transcription factor related to 
the Drosophila pair-rule gene odd skipped (Odd). Odd1 is 
expressed before all previously described kidney-regulatory 
genes, and its expression is confi ned to undiff erentiated 
kidney precursor tissue. Loss-of-function studies in the 
mouse revealed a requirement for Odd1 in the establishment 
of the metanephric mesenchyme and activation of a set of 
the earliest known genes expressed during metanephric 
kidney formation. Gain-of-function studies in the chick 
embryo revealed that Odd1 can activate early markers 
of kidney precursor cells but inhibits the production of 
diff erentiated kidney tubules. On the basis of these studies, 
James et al. propose that Odd1 plays an important role in 
the establishment and maintenance of the nephrogenic 
mesenchyme, the precursor gene from which the kidney is 
derived. (Development 2006; 133: 2995–3004)
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VEGF modulates hepatic 
erythropoiesis 
Vascular endothelial growth factor (VEGF) is an important 
angiogenic factor that has been a target of many therapeutic 
strategies for cancer and ocular disorders. Pharmacologic VEGF 
inhibitors such as antibodies specifi c for VEGF, soluble VEGF 
receptors (VEGFRs), and small-molecule antagonists of the 
VEGFR tyrosine kinase domains have led to the discovery of 
diverse VEGF functions such as corpus luteum angiogenesis, 
bone formation, glomerular permeability, and preeclampsia. 
Th ese functions of VEGF are relevant to the identifi cation of 
dose-limiting clinical toxicities for VEGF inhibition. 
In a recent article in Nature Medicine, Tam et al. observed 
increased hematocrit (60%–75%) in both mice and primates 
aft er high-grade inhibition of VEGF by diverse methods 
including adenoviral expression of soluble VEGFR ectodomains, 
recombinant VEGF Trap protein, and the VEGFR2-selective 
antibody. High-grade inhibition of VEGF induced hepatic 
synthesis of erythropoietin (Epo) more than 40-fold through an 
HIF-1 -independent mechanism, in parallel with suppression 
of renal Epo mRNA. Studies using hepatocyte-specifi c deletion 
of the vegfa gene and hepatocyte–endothelial cell co-cultures 
indicated that blockade of VEGF induced hepatic Epo by 
interfering with homeostatic VEGFR2-dependent paracrine 
signaling involving interactions between hepatocytes and 
endothelial cells. Th ese data indicate that VEGF is a previously 
unsuspected negative regulator of (dormant) hepatic Epo 
synthesis and erythropoiesis. Levels of Epo and erythrocytosis 
could represent noninvasive surrogate markers for stringent 
blockade of VEGF in vivo. (Nat Med 2006; 12: 793–800)
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Expression of Odd1 in the mouse embryo.
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Hepatocyte-derived VEGF-A stimulates VEGFR2 on adjacent liver 
sinusoidal endothelial cells (LSECs), leading to the lack of an LSEC-
derived factor(s) stimulating production of Epo by hepatocytes.
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